Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma

Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma

Immunotherapy targeting T-cell inhibitory receptors, namely programmed cell death-1 (PD-1) and/or cytotoxic T-lymphocyte associated protein-4 (CTLA-4), leads to durable responses in a proportion of patients with advanced metastatic melanoma. Combination immunotherapy results in higher rates of respo...

Full description

Bibliographic Details
Main Authors: Elena Shklovskaya, Jenny H Lee, Su Yin Lim, Ashleigh Stewart, Bernadette Pedersen, Peter Ferguson, Robyn PM Saw, John F Thompson, Brindha Shivalingam, Matteo S Carlino, Richard A Scolyer, Alexander M Menzies, Georgina V Long, Richard F Kefford, Helen Rizos
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Cancers
Subjects:
immune checkpoint blockade
anti-PD-1
combination immunotherapy
major histocompatibility (MHC) class I
metastatic melanoma
Online Access:https://www.mdpi.com/2072-6694/12/11/3374

Internet

https://www.mdpi.com/2072-6694/12/11/3374

Similar Items